Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Events In Europe Trigger Rough Patch In Markets

Published 02/08/2013, 01:43 AM
Updated 07/09/2023, 06:31 AM

2013 had one of the best Januaries in recent history, only to hit a rough patch in the first week of February. Though the markets were due for a breather, events in Europe were the trigger.

The two European countries most likely to cause the next phase of eurocrisis—Italy and Spain—both had potentially destabilizing political developments. In Italy, former prime minister (and current billionaire playboy) Silvio Berlusconi—the man most responsible for Italy’s financial malaise—has been gaining in the polls by making promises to roll back some of the economic reforms pushed through by Mario Monti’s government. These would be the same economic reforms that calmed the bond market and helped to restore confidence in Italy.

And in Spain, Prime Minister Mariano Rajoy has been implicated in a corruption scandal that threatens his government…at the same time that Catalonia is agitating for independence.

At this point, Sizemore Capital sees this as a mild correction in the midst of a bull market that likely has several years left to run. But it may get choppy for a few weeks.

Sizemore Capital made several portfolio moves in January and early February. In the Dividend Growth Portfolio, we sold our position in Spirit Realty Capital (SRC) following the announcement that it was to be acquired by Cole Credit Property Trust II, a non-traded REIT. Given the legal uncertainty facing the acquisition (there are multiple lawsuits from disgruntled shareholders), taking our profits seemed the more prudent course of action.

Abbott Labs (ABT) divested its pharmaceutical business as a separate stock—AbbVie (ABBV). Sizemore Capital is attracted to Abbott for its collection of stable businesses in nutrition, medical devices and over-the-counter drugs, but the pharmaceutical spinoff was a bad fit for the Dividend Growth Portfolio. We sold our shares of AbbVie and reinvested the proceeds in additional shares of Abbott.

Finally, to round out our REIT exposure, we added a position to Healthcare Trust of America (HTA), a REIT specializing in medical office buildings. Sizemore Capital is attracted to HTA’s medical property portfolio, as it is supported by strong demographic trends and should actually benefit from ObamaCare.

Sizemore Capital also made minor adjustments to the Tactical ETF Portfolio. We reduced our exposure to Africa via the Market Vectors Africa Index ETF (AFK) and invested the proceeds in the iShares FTSE China 25 Index Fund (FXI). Additionally, we slightly reduced our exposure to U.S. large cap dividend payers via the Wisdom Tree Large Cap Dividend ETF (DLN) and initiated a new position in the iShares MSCI France ETF (EWQ).

This is consistent with Sizemore Capital’s view that Europe and China represent better bargains for investors at current prices.

We made one addition to the Sizemore Investment Letter Portfolio, initiating a position in the tech start-up fund GSV Capital (GSVC). After the drubbing Facebook (FB) took in 2012, we expect a rebound in “Web 2.0” stocks, and GSV is uniquely positioned to benefit.

And finally, we replaced our bond index exposure in the Strategic Growth Allocation with active management in the form of the Pimco Total Return Bond ETF (BOND).

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.